unknown
Stage
2
Investors
About
AOA Dx develops AI-enabled blood tests for early detection of ovarian cancer and other women’s health cancers using a multi-omics platform (GlycoLocate) and lipidomics-based biomarkers (AKRIVIS GD™). The company combines lipidomics, other complementary biomarkers, and data science to identify early-stage disease from blood samples.
Explore AOA Dx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.